DK1335930T3 - Fremgangsmåde til fremstilling af 3-oxo-4-azasteroider - Google Patents

Fremgangsmåde til fremstilling af 3-oxo-4-azasteroider

Info

Publication number
DK1335930T3
DK1335930T3 DK01988307T DK01988307T DK1335930T3 DK 1335930 T3 DK1335930 T3 DK 1335930T3 DK 01988307 T DK01988307 T DK 01988307T DK 01988307 T DK01988307 T DK 01988307T DK 1335930 T3 DK1335930 T3 DK 1335930T3
Authority
DK
Denmark
Prior art keywords
azasteroids
oxo
preparation
compounds
ammonium
Prior art date
Application number
DK01988307T
Other languages
English (en)
Inventor
Roman Davis
Alan Millar
Jeffrey Thomas Sterbenz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1335930T3 publication Critical patent/DK1335930T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01988307T 2000-11-03 2001-11-02 Fremgangsmåde til fremstilling af 3-oxo-4-azasteroider DK1335930T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0026876.3A GB0026876D0 (en) 2000-11-03 2000-11-03 Process
PCT/US2001/048173 WO2002046207A2 (en) 2000-11-03 2001-11-02 Process

Publications (1)

Publication Number Publication Date
DK1335930T3 true DK1335930T3 (da) 2005-02-14

Family

ID=9902484

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01988307T DK1335930T3 (da) 2000-11-03 2001-11-02 Fremgangsmåde til fremstilling af 3-oxo-4-azasteroider

Country Status (23)

Country Link
US (1) US6794508B2 (da)
EP (1) EP1335930B1 (da)
JP (1) JP4257117B2 (da)
KR (1) KR100821018B1 (da)
CN (1) CN1313480C (da)
AT (1) ATE279429T1 (da)
AU (2) AU2002241624B2 (da)
BR (1) BR0115089A (da)
CA (1) CA2427709A1 (da)
DE (1) DE60106482T2 (da)
DK (1) DK1335930T3 (da)
ES (1) ES2230383T3 (da)
GB (1) GB0026876D0 (da)
HU (1) HUP0303907A3 (da)
IL (2) IL155078A0 (da)
MX (1) MXPA03003925A (da)
NO (1) NO325180B1 (da)
NZ (1) NZ525168A (da)
PL (1) PL206539B1 (da)
PT (1) PT1335930E (da)
SI (1) SI1335930T1 (da)
WO (1) WO2002046207A2 (da)
ZA (1) ZA200302560B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100503193B1 (ko) * 2002-08-19 2005-07-25 한미약품 주식회사 3-옥소-4-아자-5α-안드로스탄 화합물의 선택적인 제조방법
WO2005075497A1 (en) * 2004-01-07 2005-08-18 Ranbaxy Laboratories Limited PROCESS FOR THE PREPARATION OF 17ß-SUBSTITUTED-3-OXO-4-AZA-5ALPHA-ANDROSTANE DERIVATIVES
CN100355772C (zh) * 2005-12-28 2007-12-19 天津大学 具有5α-还原酶抑制活性的甾体化合物及其制备方法
AR070313A1 (es) * 2008-01-03 2010-03-31 Gador Sa Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
HU230730B1 (hu) 2011-06-30 2017-12-28 Richter Gedeon Nyrt Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059097A (zh) * 2011-10-20 2013-04-24 连云港润众制药有限公司 一种度他雄胺中间体的制备方法
CN103254268A (zh) * 2013-05-16 2013-08-21 寿光市富康化学工业有限公司 一种制备度他雄胺的工艺
CN104231033B (zh) * 2014-09-17 2016-08-24 广东众生药业股份有限公司 一种度他雄胺的制备方法
CN108051513B (zh) * 2017-11-27 2020-09-29 重庆华邦制药有限公司 Hplc法分离测定度他雄胺起始原料sm2及其相关杂质的方法
CN109438549B (zh) * 2018-12-13 2022-01-04 湖北葛店人福药业有限责任公司 一种制备N-叔丁基-3-氧代-4-氮杂-5α-雄甾-17β-甲酰胺的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB2264494A (en) * 1992-02-25 1993-09-01 Merck & Co Inc 17b-n-monosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-1-en-3-one testosterone-5-alpha reductase inhibitors
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones

Also Published As

Publication number Publication date
IL155078A0 (en) 2003-10-31
CN1473165A (zh) 2004-02-04
EP1335930B1 (en) 2004-10-13
MXPA03003925A (es) 2003-08-19
NO325180B1 (no) 2008-02-11
DE60106482T2 (de) 2005-10-13
JP2004515505A (ja) 2004-05-27
CA2427709A1 (en) 2002-06-13
NO20031995L (no) 2003-05-02
IL155078A (en) 2009-06-15
AU4162402A (en) 2002-06-18
HK1058799A1 (en) 2004-06-04
KR100821018B1 (ko) 2008-04-08
CN1313480C (zh) 2007-05-02
AU2002241624B2 (en) 2004-10-28
PL206539B1 (pl) 2010-08-31
US20040049042A1 (en) 2004-03-11
ATE279429T1 (de) 2004-10-15
GB0026876D0 (en) 2000-12-20
WO2002046207A3 (en) 2003-03-20
HUP0303907A2 (hu) 2004-03-01
BR0115089A (pt) 2003-10-07
ZA200302560B (en) 2004-04-01
SI1335930T1 (en) 2005-04-30
EP1335930A2 (en) 2003-08-20
NO20031995D0 (no) 2003-05-02
WO2002046207A2 (en) 2002-06-13
NZ525168A (en) 2005-03-24
KR20030081326A (ko) 2003-10-17
PL365705A1 (en) 2005-01-10
ES2230383T3 (es) 2005-05-01
US6794508B2 (en) 2004-09-21
PT1335930E (pt) 2005-01-31
HUP0303907A3 (en) 2012-09-28
DE60106482D1 (de) 2004-11-18
JP4257117B2 (ja) 2009-04-22

Similar Documents

Publication Publication Date Title
BR0113670A (pt) Composição farmacêutica e método para tratar hipogonadismo
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
PT1196414E (pt) Pro-farmacos de inibidores carbamato de impdh
NO20020925L (no) N-heterosykliske derivater av NOS-inhibitorer
ATE363280T1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
NO20031995D0 (no) Fremgangsmåte
BRPI0408555A (pt) sistema de liberação controlada
NO20050091L (no) Fremgangsmater for fremstilling av fibrinogen
DE60203013D1 (de) 17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe
DE60017878D1 (de) Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
DE60021113D1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
UY26133A1 (es) Derivado sustituido de pirazol.
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
DE60001850D1 (de) Chalcon coumarine
DK1347764T3 (da) Gelpræparat på alkoholisk basis til behandling af hypogonadisme ved transskrotal applikation
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
BRPI0507987A (pt) métodos e compostos moduladores receptor de glicocorticóide
PT1165595E (pt) Derivados de acidos biliares especificos do figado provenientes do antagonista do glicocorticoide ru486
AU2003266093A1 (en) Cyclooct-(en-)yl derivatives for use as fragrances
ATE364619T1 (de) Tibolonformulierungen
DK1173065T3 (da) Anvendelse af cellulosemikrofibriller i fermenterede mælkepræparater
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
DE59910761D1 (de) Verfahren zur hydrierung von ungesättigten heterocyclischen verbindungen
ECSP003466A (es) Derivado sustituido de pirazol
ECSP003326A (es) 1,2,3,4,5,6 - hexahidro- 2,6 - metano - 3 - benzazocin - 10 - oles sustituidos con n- (5- fenil- tetahidrofuranil) metilo y n-(6-feniltetrahidropiranil) metilo; procedimientos para prepararlos y su empleo como composiciones farmaceuticas